Background: Premature discontinuation of and reduced adherence to antiplatelet therapy have been identified as major risk factors for stent thrombosis and poor prognosis after acute coronary syndrome.
Aim: We aimed to identify correlates of non-adherence to aspirin among patients who had undergone coronary stenting.
Methods: We prospectively included all patients who had undergone coronary stenting in our institution. Response to aspirin was assessed during the hospital phase with arachidonic acid-induced platelet aggregation (AA-Ag) and only good responders to aspirin (AA-Ag<30%) were included in the study for longitudinal assessment (n=308). Response to aspirin was reassessed 1 month after hospital discharge and non-responders received a directly observed intake of aspirin to exclude any biological non-response due to bioavailability problems. After excluding patients with such problems, response to aspirin based on platelet function testing was used to estimate non-adherence to aspirin after coronary stenting. A logistic regression model was used to identify predictors of non-adherence.
Results: Non-adherence to aspirin concerned 14% of the study sample (n=43). After adjustment for age, those who reported the highest risk of non-adherence to aspirin were migrants (odds ratio [95% confidence interval], 8.3 [3.5-19.8], followed by patients receiving treatment for diabetes (4.5 [1.9-10.9]). Smokers had a threefold risk of non-adherence (3.1 [1.4-6.9]).
Conclusions: Non-adherence to aspirin is relatively frequent in populations at high risk of cardiovascular events. Appropriate case management and special interventions targeting these groups need to be implemented to avoid fatal events and assure long-term adherence to treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acvd.2011.03.091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive modeling of medication adherence in post myocardial infarction patients: a bayesian approach using beta-regression.
Eur J Prev Cardiol
October 2024
Department of Clinical Biochemistry and Pharmacology Faculty of Health Sciences, Ben-Gurion University of the Negev, PO Box 653, Beer-Sheva 8410501, Israel.
Aims: Predicting medication adherence in post myocardial infarction (MI) patients has the potential to improve patient outcomes. Most adherence prediction models dichotomize adherence metrics and status. This study aims to develop medication adherence prediction models that avoid dichotomizing adherence metrics and to test whether a simplified model including only 90-days adherence data would perform similarly to a full multivariable model.
View Article and Find Full Text PDFAspirin Responsiveness in a Cohort of Pediatric Patients with Right Ventricle to Pulmonary Artery Conduits and Transcatheter Valve Replacement Systems.
Pediatr Cardiol
March 2024
Department of Paediatric Cardiology, Children's Health Ireland at Crumlin, Dublin, Ireland.
The aim of this study was to determine the rate of aspirin responsiveness in a cohort of pediatric patients with in situ xenograft valved right ventricle to pulmonary artery (RV-PA) conduits and/or transcatheter valve replacements (TVR). Aspirin is routinely prescribed to these patients. Optimizing anti-platelet therapy could promote valve longevity and reduce the risk of infective endocarditis in this at-risk group.
View Article and Find Full Text PDFLong-term aspirin adherence following myocardial infarction and risk of cardiovascular events.
Eur Heart J Qual Care Clin Outcomes
November 2024
Department of Cardiology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, 2000 Frederiksberg, Copenhagen, Denmark.
Aims: Aspirin is considered mandatory after myocardial infarction (MI). However, its long-term efficacy has been questioned. This study investigated the effectiveness of long-term aspirin after MI.
View Article and Find Full Text PDFBleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Health Technol Assess
May 2023
Bristol Trials Centre, University of Bristol, Bristol, UK.
Article Synopsis
- This study investigates bleeding risks associated with different antiplatelet therapies and triple therapy in patients undergoing heart procedures or managed for acute coronary syndrome.
- The research aims to analyze hazard ratios for bleeding events, resource utilization, and costs related to these events while also enhancing cost-effectiveness models for dual antiplatelet therapy.
- Conducted in England from 2010 to 2017, the study includes patients aged 18 and older and utilizes data from clinical and hospital records to assess outcomes related to various treatment regimens.
Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis.
Curr Cardiol Rep
July 2023
School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Purpose Of Review: Dual antiplatelet therapy (DAPT)-aspirin in conjunction with a P2Y inhibitor-is the cornerstone of managing patients with acute coronary syndromes post-revascularization, but the clinical response is highly variable, with potentially devastating consequences. Herein, we review the mechanisms underpinning said variability and explore emerging approaches to normalizing therapeutic benefit.
Recent Findings: The potent P2Y inhibitors, prasugrel and ticagrelor, exhibit minimal inter-individual variability, replacing clopidogrel in DAPT and achieving greater rates of therapeutic response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!